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Abstract 
Collagen VI is a ubiquitous heterotrimeric protein of the ECM with a complex assembly 
process and a multiplicity of functions. In skeletal muscle, collagen VI provides both 
structural integrity to the endomysium and basement membrane surrounding muscle fibres 
and also provides signalling cues to underlying satellite cells in the growth and regeneration 
of skeletal muscle. Mutations in collagen VI lead to a spectrum of congenital myopathies, 
from the relatively mild Bethlem Myopathy to the severe Ullrich Congenital Muscular 
Dystrophy. 
The multi-subunit composition of collagen VI contains predominantly von Willebrand Factor 
type A domains (VWA), which are protein protein interaction domains found in a range of 
ECM proteins. The α3(VI) chain in particular has up to ten VWA domains at its N terminus 
joined end to end. Here, it is demonstrated that the flexibility between these domains, thus 
far only experimentally hinted at, is indeed present. The flexibility between adjacent domains 
ranges from an elastic stiff spring type in distal tandem domains (after N4) to a highly flexible 
linker between the N4-N3 domains, indicating a hinge-like mechanism in the latter region. 
Pathogenic mutations are uncommon in this region of the α3(VI) chain, suggesting an 
integral role which is intolerant to variants that compromise these structural features. 
Disease causing mutations are however common in the triple helical region and flanking 
VWA domains. The α3(VI) N2 VWA domain is one such domain and the solved crystal 
structure was helpful to understand the pathomechanisms. The consequences of point 
mutations introduced into the single N2 domain depends on the location within the structure 
resulting in either misfolding, retention and triggering of ER stress or secretion into the ECM 
to form aberrant interactions. Tentative structure function relationships were thus explored. 
These fundamental disease-causing mechanisms are also paralleled by mutations occurring 
in the triple helical region. A splice site mutation in COL6A1 (c.930+189C>T) leading to the 
inclusion of a pseudoexon and a 24 residue interruption to the Gly-Xaa-Yaa repeat, results in 
a rapidly progressive form of UCMD. The resulting mutant α1(VI) chain is shown to be largely 
secreted as a non-triple helical form into the ECM of dermal fibroblasts, notwithstanding a 
degree of intracellular retention of high molecular weight aggregates which may trigger ER 
stress. The mutant α1(VI) chain then accumulates in the ECM of skeletal muscle and that 
deposited by cultured dermal fibroblasts, where it exists in cluster-like formations which 
interact with wild-type collagen VI. This chain therefore seems to act primarily via a gain-of-
misfunction, toxic pathomechanism, representing a novel disease paradigm for a collagen VI 
myopathy. Thus, biochemical characterisation of this mutation has proved valuable in the 
development of a promising oligonucleotide skipping based therapy for this form of UCMD. 
